Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. Statistics
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. (6NQ) Stock Statistics & Valuation Metrics
Total Valuation
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. has a market cap or net worth of EUR 46.59M. The enterprise value is EUR 288.42T.
- Market Cap
- EUR 46.59M
- Enterprise Value
- EUR 288.42T
Share Statistics
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. has 76,019,400 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 76,019,400
- Owned by Insiders
- ―
- Owned by Institutions
- <0.01%
Financial Efficiency
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.’s return on equity (ROE) is -0.16 and return on invested capital (ROIC) is -6.83%.
- Return on Equity (ROE)
- -0.16
- Return on Assets (ROA)
- -0.07
- Return on Invested Capital (ROIC)
- -6.83%
- Return on Capital Employed (ROCE)
- -0.12
- Revenue Per Employee
- 196.30K
- Profits Per Employee
- -93.14K
- Employee Count
- 214
- Asset Turnover
- 0.14
- Inventory Turnover
- 2.36
Valuation Ratios
The current PE Ratio of Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. is -9.29. Biomed-Lublin Wytwornia Surowic i Szczepionek S.A.’s PEG ratio is -0.03.
- PE Ratio
- -9.29
- PS Ratio
- 4.13
- PB Ratio
- 1.69
- Price to FCF
- -13.24
- Price to Operating Cash Flow
- -658.33
- PEG Ratio
- -0.03
Income Statement
In the last 12 months, Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. had revenue of 42.01M and earned -19.93M in profits. Earnings per share was -0.27.
- Revenue
- 42.01M
- Gross Profit
- 12.99M
- Operating Income
- -20.58M
- Pretax Income
- -23.91M
- Net Income
- -19.93M
- EBITDA
- -7.28M
- Earnings Per Share (EPS)
- -0.27
Cash Flow
In the last 12 months, operating cash flow was -305.00K and capital expenditures -14.91M, giving a free cash flow of -15.21M billion.
- Operating Cash Flow
- -305.00K
- Free Cash Flow
- -15.21M
- Free Cash Flow per Share
- -0.20
Dividends & Yields
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -7.55%
- Earnings Yield
- -10.46%
Stock Price Statistics
- Beta
- 0.72
- 52-Week Price Change
- -37.14%
- 50-Day Moving Average
- 0.64
- 200-Day Moving Average
- 0.72
- Relative Strength Index (RSI)
- 51.74
- Average Volume (3m)
- ―
Financial Position
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. as a current ratio of 0.90, with Debt / Equity ratio of 67.89%
- Current Ratio
- 0.90
- Quick Ratio
- 0.81
- Debt to Market Cap
- 0.30
- Net Debt to EBITDA
- -11.39
- Interest Coverage Ratio
- -5.21
Taxes
In the past 12 months, Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. has paid -3.98M in taxes.
- Income Tax
- -3.98M
- Effective Tax Rate
- 0.17
Enterprise Valuation
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. EV to EBITDA ratio is -49.11, with an EV/FCF ratio of -19.19.
- EV to Sales
- 5.99
- EV to EBITDA
- -49.11
- EV to Free Cash Flow
- -19.19
- EV to Operating Cash Flow
- -957.41
Balance Sheet
Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. has EUR 350.00K in cash and marketable securities with EUR 90.91M in debt, giving a net cash position of -EUR 90.56M billion.
- Cash & Marketable Securities
- EUR 350.00K
- Total Debt
- EUR 90.91M
- Net Cash
- -EUR 90.56M
- Net Cash Per Share
- -EUR 1.19
- Tangible Book Value Per Share
- EUR 1.51
Margins
Gross margin is 49.60%, with operating margin of -38.87%, and net profit margin of -43.06%.
- Gross Margin
- 49.60%
- Operating Margin
- -38.87%
- Pretax Margin
- -51.74%
- Net Profit Margin
- -43.06%
- EBITDA Margin
- -12.20%
- EBIT Margin
- -39.24%
Analyst Forecast
The average price target for Biomed-Lublin Wytwornia Surowic i Szczepionek S.A. is ―, which is 11.43% higher than the current price. The consensus rating is ―
- Price Target
- ―
- Price Target Upside
- ―
- Analyst Consensus
- ―
- Analyst Count
- ―
- Revenue Growth Forecast
- -21.24%
- EPS Growth Forecast
- -1860.53%
